Abstract
The proceedings contain 15 papers The topics discussed include: targeting neuroinflammation with human umbilical cord tissue-derived mesenchymal stromal cells;multiple doses of umbilical cord blood cells improve long-term perinatal brain injury;COVID-19 and its impact on collection and processing of cord blood units at the Cleveland Cord Blood Center;hydrocortisone-treated DUOC-01, a cord blood-derived cell therapy product, ameliorates experimental autoimmune encephalomyelitis;measuring microglial suppression with multiple assays;impact of donor age on outcomes in hematopoietic stem cell transplantation;single UM171-expanded cord blood transplants support robust T-cell reconstitution with low rates of severe infections;autologous umbilical cord blood-derived cell administration in extreme preterm infants: CORD-SAFE study;and umbilical cord blood infusion reactions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
